Cumulus Oncology and leadXpro Announce Collaboration to Develop Small Molecules against Novel Cancer-Focused GPCR Targets
Cumulus Oncology and leadXpro Announce Collaboration.
Resulting IP will be licensed into a newly created Cumulus company
Henrique Costa
About Henrique Costa
Posts by Henrique Costa:
SCIENTIFIC WEBINAR
Early drug discovery requires an interdisciplinary approach with a sophisticated interplay between empirical methods and rational design. Amongst the different therapeutic modalities, orally available small molecules are a major pillar for safe treatment of acute and chronic diseases.
RaQualia Pharma and leadXpro Announce Collaboration to Accelerate Drug Discovery on Intractable Membrane Protein Targets
In this collaboration, leadXpro will establish robust protocols and workflows to facilitate the rapid determination
Septerna Engages leadXpro to Discover Novel Binding Partners to GPCR Targets for use in Internal Drug Discovery Programs
During this engagement, leadXpro will use membrane proteins selected by Septerna to discover novel binding partners to…
First CrySol VitroJet in Switzerland
We are thrilled to announce that leadXpro has extended its cryo-EM facility with the latest technology in sample preparation solution, the VitroJet. This cutting-edge technology is the first of its kind in Switzerland.
leadXpro has just elucidated the world’s first structure of a proton-sensing GPCR target
To date, no structural information has been reported for the entire H+ activated GPCR family.